December 8, 2025BloodOpen Access

Prophylactic rituximab administered on day -1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis found rituximab reduces EBV reactivation and viral load in pediatric HSCT, suggesting a beneficial prophylactic strategy.

EBV reactivation significantly lower at 10.1% with rituximab compared to 47.0% without treatment, demonstrating its effectiveness.
Multivariable analysis shows rituximab independently associated with a HR of 0.145 for reduced EBV risk in treated patients.
Analysis used propensity-matched cohort with logistic regression to establish balance, ensuring robust assessment of outcomes.
Prophylactic rituximab shows promise in pediatric allo-HSCT, with temporary delays in immune reconstitution but no increase in complications.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis found rituximab reduces EBV reactivation and viral load in pediatric HSCT, suggesting a beneficial prophylactic strategy.